Regarding PTH analogs, one of the studies included in this analysis indicated that treatment with only teriparatide at 40 μg/day in patients with mild CKD resulted in a significant improvement in eGFR, whereas other interventions had no substantial effect and may lead to adverse events, such as hypercalcemia and hyperuricemia (Miller et al., 2007). This evidence concerns the gene PTH and chronic kidney disease.